Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

BACKGROUND: Type 2 diabetes (T2D) is strongly associated with cardiovascular risk and requires medications that improve glycemic control and other cardiovascular risk factors. The authors aimed to assess the relative effectiveness of pioglitazone (Pio), metformin (Met) and any sulfonylurea (SU) comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez, Ángel, Reviriego, Jesús, Karamanos, Vasilios, del Cañizo, Francisco J, Vlachogiannis, Nikolaos, Drossinos, Vangelis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042924/
https://www.ncbi.nlm.nih.gov/pubmed/21314919
http://dx.doi.org/10.1186/1475-2840-10-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042924/
https://www.ncbi.nlm.nih.gov/pubmed/21314919
http://dx.doi.org/10.1186/1475-2840-10-18

Ejemplares similares